logo-loader
viewIXICO PLC

Notice of Results

/**/ h1{margin-top:24.0pt;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;line-height:115%;font-size:14.0pt;font-family:"Calibri","sans-serif";color:#31849B;font-weight:bold;}h2{margin-top:10.0pt;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;line-height:115%;font-size:13.0pt;font-family:"Calibri","sans-serif";color:#31849B;font-weight:bold;}h3{margin-top:12.0pt;margin-right:0cm;margin-bottom:3.0pt;margin-left:0cm;line-height:115%;font-size:13.0pt;font-family:"Calibri Light","sans-serif";font-weight:bold;}h4{margin-top:2.0pt;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;line-height:115%;font-size:11.0pt;font-family:"Cambria","serif";color:#365F91;font-weight:normal;font-div:italic;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: purple } .ah{size:595.3pt 841.9pt;margin:2.0cm 2.0cm 2.0cm 2.0cm;}div.ah{}p.bg{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";line-height: normal; margin-bottom: 0cm; text-align: right}span.be{color:black}p.ad,li.ad,div.ad{margin:0cm;margin-bottom:.0001pt;text-align:center;font-size:12.0pt;font-family:"Calibri","sans-serif";font-weight:bold;}span.bh{font-family:"Arial","sans-serif";font-size:11.0pt;font-family:"Calibri","sans-serif"}p.bi{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif"; font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: center}p.bj{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;line-height:normal;background:white}p.bk{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;line-height:normal}p.bl{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; margin-left: 0cm; margin-right: -12.5pt; margin-top: 0cm; text-align: justify} table.bm{margin-left:-5.4pt;border-collapse:collapse}td.av{width:286.65pt;padding:0cm 5.4pt 0cm 5.4pt}p.bn{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; margin-bottom: 11.0pt}span.ax{font-size: 10.0pt;line-height:115%;color:black}td.as{width:142.55pt;padding:0cm 5.4pt 0cm 5.4pt}p.bo{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:11.0pt;text-align:justify}span.au{font-size:10.0pt;line-height:115%;color:black}p.bp{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:11.0pt}span.ar{font-size:10.0pt; line-height:115%;color:black}p.bq{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; margin-bottom: 11.0pt; text-align: justify} p.br{margin-top:0cm;margin-right:0cm;margin-bottom:13.5pt;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify}span.bs{color: black; font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold}p.bt{margin-top:0cm;margin-right:0cm;margin-bottom:13.5pt;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin-bottom: 0cm; text-align: justify}span.al{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black}span.bu{color:black}span.bv{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}span.bc{font-size:11.0pt;font-family:"Calibri","sans-serif"}span.bw{color:blue;text-decoration:underline;font-family: "Calibri","sans-serif"; font-size: 11.0pt; text-decoration: none} /**/
RNS Number : 5887Y
IXICO plc
10 May 2019
 

10 May 2019

IXICO plc

("IXICO" or the "Company")

 

Notice of Results

 

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, will announce its interim results for the six months ended 31 March 2019 on Wednesday, 22 May 2019.

 

Giulio Cerroni, CEO and Grant Nash, CFO, will host a breakfast briefing and call for analysts at 09:00 BST on the day of the results at Cenkos Securities, 6-8 Tokenhouse Yard, London EC2R 7AS.

 

For further information please contact:

 

IXICO plc

+44 (0) 20 3763 7498

Giulio Cerroni, Chief Executive Officer




Cenkos Securities PLC (Nominated adviser and sole broker)

+44 (0) 20 7397 8900

Giles Balleny / Max Gould (Corporate Finance)


Michael F Johnson / Russell Kerr (Sales)




Optimum Strategic Communications

 +44 (0) 203 950 9144

Mary Clark / Anne Marieke Ezendam / Supriya Mathur


[email protected]


 

About IXICO

 

IXICO is dedicated to delivering insights in neuroscience. Our mission is to transform the progression of our biopharmaceutical clients' neurological therapeutic pipelines through the application of novel imaging and digital biomarkers.

 

IXICO's data analytics services are used by the global biopharmaceutical industry to interpret data from brain scans and digital biosensors to enable better trial design, site qualification, patient selection and clinical outcomes. We provide technology-enabled services across all phases of clinical evaluation. Our integrated digital platform provides a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable clients to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new analytical techniques and companion digital health products targeted at improving patient outcomes.

 

More information is available on www.IXICO.com

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NORDBGDUGBGBGCC

Quick facts: IXICO PLC

Price: 72

Market: AIM
Market Cap: £33.77 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Proactive meets IXICO's new chief business officer Lammert...

Lammert Albers sits down with Proactive London's Andrew Scott soon after his appointment as IXICO PLC’s (LON:IXI) chief business officer. With expertise of the Alzheimer's disease trials market he says he'll be responsible for executing the company's global business development strategy in...

2 weeks, 1 day ago